$ALHC

KAO JOHN E sold $5.9M of ALHC (indirect holdings)

KAO JOHN E (Chief Executive Officer) sold 298,000 indirectly-held shares of Alignment Healthcare, Inc. (ALHC) at an average of $19.86 ($19.81–$20.65, $5.92M total) across 2 trades on 2026-07-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KAO JOHN E
Published Jul 14, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 14, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
high confidence
Mentioned
$ALHC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The disclosed event is an open-market sale by the CEO through a pre-arranged 10b5-1 plan; absent other news, it typically does not change fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing alone is unlikely to drive a sustained repricing.

03

What to watch

The article does not disclose total insider ownership changes beyond the post-transaction share count, nor does it provide context on prior sales frequency or remaining plan schedule.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-14 after-hours; transaction dated 2026-07-10.

Background

The article is a SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralHigh confidence
Context

CEO John E. Kao sold $5.9M of Alignment Healthcare shares via a 10b5-1 plan, with 298,000 shares sold at $19.81–$20.65.

Expected impact

Likely limited near-term impact; any effect is typically short-lived unless accompanied by other negative disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly marked as pre-arranged 10b5-1, with no accompanying operational, regulatory, or financial guidance changes in the text.

Market effects

No sector-level read-through is provided; this is company-specific insider selling.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can reflect planned liquidity needs rather than bearish expectations, so the market may ignore it.

Key entities

  • Alignment Healthcare, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • John E. Kao

    CEO and reporting person who sold shares via a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMed

Why Alignment Healthcare (ALHC) Stock Is Up Today

Alignment Healthcare (ALHC) shares rose 8.6% after its subsidiary announced a new Medicare Advantage plan in Los Angeles and Orange counties. Analyst Ryan Langston lowered his price target to $12 but maintained a Buy rating, citing inpatient utilization pressure. The stock had fallen 13.4% the previous day due to a downgrade and regulatory concerns.

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$ALHCHigh

ALHC Stock Slides As Legal, Cost, And Rating Pressures Mount

Alignment Healthcare Inc. (ALHC) stock fell 14.75% on October 9, 2026, amid concerns over Medicare Advantage reimbursement pressures, legal issues, and cost challenges. The company reported $1.34B in revenue and $36.6M in net income for the latest quarter, but negative cash flow raised concerns. CMS's 2027 Star Ratings and a whistleblower's accounting allegations further pressured the stock, with Barclays cutting its price target to $10.